Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21114190 | 0.84 | FEN1 (0.46) | KDM4ETP53L3MBTL1ALOX5APFEN1 | |
| SCHEMBL21163425 | 0.78 | SLC6A4 (0.40) | SLC6A4TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11662853 | 0.78 | KDM4E (0.70) | KDM4ESLC6A4TP53CYP1A2CYP3A4 | |
| SCHEMBL21163139 | 0.78 | KDM4E (0.40) | KDM4ESLC6A4TP53CYP1A2CYP3A4 | |
| SCHEMBL27844311 | 0.76 | KDM4E (0.67) | KDM4ESLC6A4TP53L3MBTL1ALDH1A1 | |
| SCHEMBL21113937 | 0.76 | L3MBTL1 (0.51) | KDM4ESLC6A4TP53CYP1A2CYP3A4 | |
| SCHEMBL21114181 | 0.75 | ALOX5AP (0.39) | KDM4ESLC6A4ALOX5APFEN1 | |
| SCHEMBL21114065 | 0.75 | PTPRC (0.55) | KDM4ETP53TSHRL3MBTL1ALOX5AP | |
| SCHEMBL21114098 | 0.74 | ALOX5AP (0.42) | KDM4ESLC6A4TP53CYP1A2CYP3A4 | |
| SCHEMBL21113978 | 0.74 | L3MBTL1 (0.50) | KDM4ESLC6A4TP53L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | KDM4E 4784/4885SLC6A4 3466/4885TP53 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.